R&D Changing Faces: Board of Directors and Advisory Boards, Febr... Boardrooms and advisory panels across pharma, biotech, medtech, and digital health were busy last month.
R&D Ending trial-and-error: How psychedelics and precision medic... The next phase of psychiatry must go toward treatments that are not only novel, but practical, personalised, and accessible.
R&D Regulatory setback or scientific signal? The case for human-... Exploring a systemic challenge in translating biological promise into reliable human efficacy and safety.
R&D BIO-Europe Spring 2026: In conversation with Robert Jacks Robert Jacks, CEO of Sparrow Pharmaceuticals, discusses the company’s work in the cardiometabolic space.
R&D Longevity is not a consumer trend, but a pipeline strategy p... Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge.
R&D Making AI work where it matters, with Rob DiCicco Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.
News ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
